EFFECT OF SITAGLIPTIN AND VILDAGLIPTIN ON WOUND HEALING IN MALE WISTAR RATS - AN EXPERIMENTAL STUDY
Objective: Diabetes mellitus (DM) is a spectrum of common metabolic disorders, arising from a variety of pathogenic mechanisms. With an increasing incidence worldwide, DM will be likely a leading cause of morbidity and mortality in the future. Delayed wound healing in diabetes is a major source of morbidity and mortality. Sitagliptin and Vildagliptin are novel antihyperglycemic agents used for the treatment of DM. The present study was planned to investigate the effect of Sitagliptin and Vildagliptin on various wound healing models in male Wistar rats.
Methods: Male Wistar rats (150â€“200 g) were divided into three groups, i.e., control, Sitagliptin, and Vildagliptin (n=6 animals in each group) for each wound model. Excision wound, resutured incision wound, and dead space wounds were inflicted under thiopentone anesthesia in male Wistar rats. The rats received Sitagliptin and Vildagliptin orally during the study period. Resutured incision was assessed by wound breaking strength; dead space wound was assessed by granuloma dry weight and histopathology of granulation tissue. In excision wounds, treatment was monitored by planimetry. Data were expressed as meanÂ±standard error of mean and analyzed by analysis of variance followed by Dunnettâ€™s post hoc test. p<0.05 was considered statistically significant.
Results: Sitagliptin and Vildagliptin significantly promoted the healing process in all three wound models studied. Histopathological studies revealed increased collagen content and granulation tissue in Sitagliptin and Vildagliptin groups.
Conclusion: In all the three wound models studied, Sitagliptin and Vildagliptin promoted wound healing. The pro-healing effect of Sitagliptin and Vildagliptin needs to be explored clinically.
2. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrisonâ€™s Principles of Internal Medicine. 18th ed. New York: McGraw Hill Publishers; 2012.
3. Pryce DT. A case of perforating ulcers of both feet associated with diabetes and ataxic symptoms. Lancet 1887;130:11-2.
4. Setacci C, de Donato G, Setacci F, Chisci E. Diabetic patients: Epidemiology and global impact. J Cardiovasc Surg (Torino) 2009;50:263-73.
5. Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality rates and diabetic foot ulcers: Is it time to communicate mortality risk to patients with diabetic foot ulceration? J Am Podiatr Med Assoc 2008;98:489-93.
6. SchÃ¼rmann C, Linke A, Pilger K, Steinmetz C, Mark M, Pfeilschifter J, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialisation in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther 2012;342:71-80.
7. Ghosh MN. Fundamentals of Experimental Pharmacology. 4th ed. Kolkata: Hilton And Company; 2005.
8. Rao KS, Patil PA, Malur PR. Promotion of cutaneous wound healing by famotidine in Wistar rats. Indian J Med Res 2007;125:149-54.
9. Turner RA. Screening Methods in Pharmacology. New York, London: Academic Press Inc; 1965.
10. Patil PA, Kulkarni DR. Effect of anti proliferative agents on healing of dead space wounds in rats. Ind J Med Res 1984;74:445-7.
11. Dâ€™Arcy PF, Howard EM, Muggleton PW, Townsend SB. The anti-inflammatory action of griseofulvin in experimental animals. J Pharm Pharmacol 1960;12:659-65.
12. Dipasquale G, Meli A. Effect of body weight changes on the formation of cotton pellet induced granuloma. J Pharm Pharmacol 1965;17:379-82.
13. Yamaguchi Y, Yoshikawa K. Cutaneous wound healing: An update. J Dermatol 2001;28:521-34.
14. Mekala S, Kumar MN, Das L, Shetty N, Amuthan A, Vulli V, et al. Evaluation of wound healing activity of ethanolic extract of Lantana camara in streptozotocin induced diabetic rats. Int J Pharm Pharm Sci 2014;6:631-3.
15. Bairy KL, Abhinav R, Satyam S. Evaluation of burn wound healing activity of topical regular insulin in non-diabetic and streptozocin-induced diabetic rats. Int J Pharm Pharm Sci 2014;6:127-30.
16. Gupta V. Pleiotropic effects of incretins. Indian J Endocrinol Metab 2012;16:S47-56.
17. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014;37:2884-94.
18. Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, Padovano V, et al. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res 2012;2012:892706.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.